Thrombocytopenia clinical trials

Explore recruiting thrombocytopenia clinical trials.

Recruiting thrombocytopenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thrombocytopenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Italy, Czechia, Poland, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Spain, Portugal, France, Italy, Romania, Greece +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3

Spain, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia

France, Italy, Denmark, Spain, Poland, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies

Germany, Spain, Belgium, Hungary, Italy, Sweden +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Thrombocytopenia trials by city

Thrombocytopenia in Toronto Thrombocytopenia in Vancouver Thrombocytopenia in Montreal Thrombocytopenia in Calgary Thrombocytopenia in Edmonton Thrombocytopenia in Ottawa Thrombocytopenia in Winnipeg Thrombocytopenia in Quebec City Thrombocytopenia in Hamilton Thrombocytopenia in Kitchener Thrombocytopenia in London Thrombocytopenia in Halifax Thrombocytopenia in New York Thrombocytopenia in Los Angeles Thrombocytopenia in Chicago Thrombocytopenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease